Fertil Steril. 2010 Mar 1;93(4):1267-72.
"Activated protein C resistance was detected in 18/251 patients (7.2%), and protein C deficiency was detected in one patient (0.4%). None of the patients developed VTE under cross-sex hormone therapy during a mean of 64.2 +/- 38.0 months. There was no difference in the incidence of thrombophilia comparing MtF and FtM transsexuals (8.0% [13/162] vs. 5.6% [5/89], respectively)."
"Cross-sex hormone therapy is feasible in MtF as well as in FtM patients with aPC resistance."
"In summary, our data indicate that cross-sex hormone therapy in FtM and MtF transsexuals with thrombophilia is safe."
Endocr Pract. 2013 Jul-Aug;19(4):644-50.
None of the 50 transmen developed DVT.
Transl Res. 2011 Oct;158(4):225-34.
6 men taking testosterone developed thrombotic complications. BUT...
"Of these 6 men, 5 were found to have previously undiagnosed factor V Leiden heterozygosity, 1 of whom had ancillary MTHFR C677T homozygosity, and 2 with ancillary MTHFR C677T-A1298C compound heterozygosity. One man had high factor VIII (195%), factor XI (179%), and homocysteine (29.3 umol/L)." So, they were all predisposed.
"Thrombotic events after starting testosterone therapy are associated with familial thrombophilia."
I don't care much for the authors' speculation as the amount of E aromatized from T is so low as to have negligible effect on coagulation, especially if you consider other studies where high doses of bio-identical E taken parenterally were given to men with prostate cancer with no significant impact on coagulation or studies in transsexual or cis- women with thrombophilia where transdermal E was prescribed and surely resulted in higher levels of E with no increase in thrombotic events.
I speculate that had they not been on testosterone, these events would have occurred anyways.
Clin Appl Thromb Hemost. 2014 Jan;20(1):22-30.
"We describe thrombosis, deep venous thrombosis (DVT) pulmonary embolism (PE; n = 9) and hip-knee osteonecrosis (n = 5) that developed after testosterone therapy (median 11 months) in 14 previously healthy patients (13 men and 1 woman; 13 Caucasian and 1 African American), with no antecedent thrombosis and previously undiagnosed thrombophilia-hypofibrinolysis. Of the 14 patients, 3 were found to be factor V Leiden heterozygotes, 3 had high factor VIII, 3 had plasminogen activator inhibitor 1 4G4G homozygosity, 2 had high factor XI, 2 had high homocysteine, 1 had low antithrombin III, 1 had the lupus anticoagulant, 1 had high anticardiolipin antibody Immunoglobulin G, and 1 had no clotting abnormalities."
"The DVT-PE and osteonecrosis after starting testosterone are associated with previously undiagnosed thrombophilia-hypofibrinolysis."
Again, I speculate that had they not taken T, same events would have unfolded. I could be wrong...